Canaccord lowered the firm’s price target on Wave Life Sciences (WVE) to $43 from $52 and keeps a Buy rating on the shares. The firm said headed into the next AATD update, focus remains on the amount of M- and total- AAT protein that can be produced with more and higher WVE-006 doses. Canaccord said they continue to think shares are trading at a significant discount following the last INHBE update/sell off.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: